2Semana·

Two Successful Phase 3 Trials for Bristol Myers Squibb

Bristol Myers Squibb stock $BMY (-1,72 %) rose 6.5% on Monday after the company announced positive topline results from two separate Phase 3 clinical trials. These trials evaluated targeted therapies for neuroendocrine tumors and idiopathic pulmonary fibrosis.

$BMY (-1,72 %)

Best regards 🌊

5 Comentarios

pivot_code@pivot_code

2Semana

So why is it going down again?

••

Poor Dad@PoorDad

2Semana

@pivot_code sell the news?

•

Fl_ow@Fl_ow

2Semana

@pivot_code

The New Jersey-based Bristol Myers said a 60 mg twice-daily dose ⁠of admilparant significantly outperformed placebo in preserving lung function after 52 weeks. But the higher 120 mg dose missed the study's main goal.

Analysts said they had tempered expectations for the results, citing safety concerns, and called for complete data to assess the commercial opportunity for the drug.

But William Blair analyst Matt Phipps said the success of the 60 mg dose could be a blockbuster opportunity, bringing in sales of about $1.3 billion in 2032.

•

Fl_ow@Fl_ow

2Semana

@pivot_code In the long term, there is definitely upside potential—at least in my opinion. If sales of the 60 mg dose bring in revenue, as mentioned.
Some patents are set to expire soon, which naturally raises the question of whether the new drugs can offset the loss.

Best regards

••

pivot_code@pivot_code

2Semana

@Fl_ow danke!

•